3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
22
Active not recruiting
15
Completed
14
Not yet recruiting
10
Unknown
7
Terminated
4
Withdrawn
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma, B-Cell
2
Burkitt Lymphoma
2
Recurrence
1
Neoplasm, Residual
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, B-Cell
1
Interventions
Cyclophosphamide
13
Peripheral Blood Stem Cell Transplantation
9
Methotrexate
9
Cytarabine
9
fludarabine phosphate
8
fludarabine
8
Radiotherapy
7
Vincristine
5
Cyclosporine
5
Whole-Body Irradiation
4
Prednisone
4
Mycophenolic Acid
4
Melphalan
4
Filgrastim
4
Etoposide
4
Busulfan
4
asparaginase erwinia chrysanthemi recombinant
3
Tacrolimus
3
Sirolimus
3
Dasatinib
3
Cord Blood Stem Cell Transplantation
3
Bortezomib
3
Asparaginase
3
prednylidene
2
pegaspargase
2
ixazomib
2
deltacortene
2
blinatumomab
2
Thiotepa
2
Therapeutics
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Withdrawn
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
blinatumomab
×
Clear all
NCT03982992
2024-03-12
DLI-TARGET
Ludwig-Maximilians - University of Munich
Phase 2
Withdrawn
NCT03628053
2020-07-09
OBERON
Novartis
Phase 3
Withdrawn